Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Fenaux

Showing results (171-180 of 432) with videos related to

Pageof 44
Sort By:
Annals of Hematology|March 28, 2025
A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndromeGuillermo Garcia-Manero, Manila Gaddh, Uwe Platzbecker, et al.
BMJ Open|July 30, 2024
Designing a single-arm phase 2 clinical trial of mitapivat for adult patients with erythrocyte membranopathies (SATISFY): a framework for interventional trials in rare anaemias - pilot study protocolAndreas Glenthøj, Eduard J van Beers, Richard van Wijk, et al.
British Journal of Haematology|August 1, 2024
Targeting the redox vulnerability of acute myeloid leukaemia cells with a combination of auranofin and vitamin CZhiliang Hei, Shujun Yang, Guifang Ouyang, et al.
Blood|May 27, 2006
Frequent antibody production against RARalpha in both APL mice and patientsMarie Robin, Juliette Andreu-Gallien, Marie-Helene Schlageter, et al.
Blood|October 30, 2009
Alpha-defensins secreted by dysplastic granulocytes inhibit the differentiation of monocytes in chronic myelomonocytic leukemiaNathalie Droin, Arnaud Jacquel, Jean-Baptiste Hendra, et al.
Haematologica|September 7, 2019
Synergistic effects of PRIMA-1<sup>Met</sup> (APR-246) and 5-azacitidine in <i>TP53</i>-mutated myelodysplastic syndromes and acute myeloid leukemiaNabih Maslah, Norman Salomao, Louis Drevon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopeniaHagop Kantarjian, Pierre Fenaux, Mikkael A Sekeres, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 25, 2016
An miRNA-DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid LeukemiaFrançoise Solly, Catherine Koering, Aminetou Mint Mohamed, et al.
British Journal of Haematology|October 15, 2021
Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registryThibault Comont, Mael Heiblig, Etienne Rivière, et al.
Hemasphere|November 15, 2019
Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNetRaphael Itzykson, Pierre Fenaux, David Bowen, et al.
Pageof 44

Showing results (171-180 of 432) with videos related to

Sort By:
Pageof 44
Annals of Hematology|March 28, 2025
A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndromeGuillermo Garcia-Manero, Manila Gaddh, Uwe Platzbecker, et al.
BMJ Open|July 30, 2024
Designing a single-arm phase 2 clinical trial of mitapivat for adult patients with erythrocyte membranopathies (SATISFY): a framework for interventional trials in rare anaemias - pilot study protocolAndreas Glenthøj, Eduard J van Beers, Richard van Wijk, et al.
British Journal of Haematology|August 1, 2024
Targeting the redox vulnerability of acute myeloid leukaemia cells with a combination of auranofin and vitamin CZhiliang Hei, Shujun Yang, Guifang Ouyang, et al.
Blood|May 27, 2006
Frequent antibody production against RARalpha in both APL mice and patientsMarie Robin, Juliette Andreu-Gallien, Marie-Helene Schlageter, et al.
Blood|October 30, 2009
Alpha-defensins secreted by dysplastic granulocytes inhibit the differentiation of monocytes in chronic myelomonocytic leukemiaNathalie Droin, Arnaud Jacquel, Jean-Baptiste Hendra, et al.
Haematologica|September 7, 2019
Synergistic effects of PRIMA-1<sup>Met</sup> (APR-246) and 5-azacitidine in <i>TP53</i>-mutated myelodysplastic syndromes and acute myeloid leukemiaNabih Maslah, Norman Salomao, Louis Drevon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopeniaHagop Kantarjian, Pierre Fenaux, Mikkael A Sekeres, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 25, 2016
An miRNA-DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid LeukemiaFrançoise Solly, Catherine Koering, Aminetou Mint Mohamed, et al.
British Journal of Haematology|October 15, 2021
Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registryThibault Comont, Mael Heiblig, Etienne Rivière, et al.
Hemasphere|November 15, 2019
Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNetRaphael Itzykson, Pierre Fenaux, David Bowen, et al.
Pageof 44